100 related articles for article (PubMed ID: 22990547)
1. EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
Marinaş MC; Mogoş G; Ciurea R; Mogoş DG
Rom J Morphol Embryol; 2012; 53(3):563-7. PubMed ID: 22990547
[TBL] [Abstract][Full Text] [Related]
2. The immunoexpression of EGFR and Her2/neu in oral squamous carcinoma.
Dragomir LP; Mărgăritescu C; Florescu A; Olimid AD; Dragomir M; Popescu MR
Rom J Morphol Embryol; 2012; 53(3):597-601. PubMed ID: 22990553
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
Brustmann H
Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
[TBL] [Abstract][Full Text] [Related]
4. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors.
Cîrstea AE; Stepan AE; Mărgăritescu C; Zăvoi RE; Olimid DA; Simionescu CE
Rom J Morphol Embryol; 2017; 58(4):1269-1273. PubMed ID: 29556616
[TBL] [Abstract][Full Text] [Related]
5. EGFR and Her2/neu immunoexpression in papillary urothelial bladder carcinomas.
Enache M; Simionescu CE; Stepan A
Rom J Morphol Embryol; 2013; 54(1):137-41. PubMed ID: 23529321
[TBL] [Abstract][Full Text] [Related]
6. Expression of cell regulatory proteins in ovarian borderline tumors.
van Haaften-Day C; Russell P; Boyer CM; Kerns BJ; Wiener JR; Jensen DN; Bast RC; Hacker NF
Cancer; 1996 May; 77(10):2092-8. PubMed ID: 8640675
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
8. P53 and Ki67 immunoexpression in mucinous malignant ovarian tumors.
Kamal CK; Simionescu CE; Mărgăritescu C; Stepan A
Rom J Morphol Embryol; 2012; 53(3 Suppl):799-803. PubMed ID: 23188443
[TBL] [Abstract][Full Text] [Related]
9. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus.
Walker F; Abramowitz L; Benabderrahmane D; Duval X; Descatoire V; Hénin D; Lehy T; Aparicio T
Hum Pathol; 2009 Nov; 40(11):1517-27. PubMed ID: 19716155
[TBL] [Abstract][Full Text] [Related]
10. Protein levels and gene expressions of the epidermal growth factor receptors, HER1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract][Full Text] [Related]
11. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
12. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis.
Rosen DG; Mercado-Uribe I; Yang G; Bast RC; Amin HM; Lai R; Liu J
Cancer; 2006 Dec; 107(11):2730-40. PubMed ID: 17063503
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors.
Khalifa MA; Lacher DA; Lage JM; Mannel RS; Walker JL; Angros LH; Min KW
Cancer Detect Prev; 1997; 21(6):532-9. PubMed ID: 9398993
[TBL] [Abstract][Full Text] [Related]
14. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
15. Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
Katori H; Nozawa A; Tsukuda M
Acta Otolaryngol; 2007 Nov; 127(11):1207-13. PubMed ID: 17851915
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
17. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables.
Sylvia MT; Kumar S; Dasari P
Indian J Pathol Microbiol; 2012; 55(1):33-7. PubMed ID: 22499297
[TBL] [Abstract][Full Text] [Related]
18. Ki67 and Bcl-2 immunoexpression in primitive urothelial bladder carcinoma.
Enache M; Simionescu C; Lascu LC
Rom J Morphol Embryol; 2012; 53(3):521-5. PubMed ID: 22990542
[TBL] [Abstract][Full Text] [Related]
19. Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Barbashina V; Benevenia J; Aviv H; Tsai J; Patterson F; Aisner S; Cohen S; Fernandes H; Skurnick J; Hameed M
J Cancer Res Clin Oncol; 2002 Nov; 128(11):610-6. PubMed ID: 12458341
[TBL] [Abstract][Full Text] [Related]
20. EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis.
Ettl T; Stiegler C; Zeitler K; Agaimy A; Zenk J; Reichert TE; Gosau M; Kühnel T; Brockhoff G; Schwarz S
Hum Pathol; 2012 Jun; 43(6):921-31. PubMed ID: 22154363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
